AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00819780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
Study NCT04320615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Study NCT02699541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education
Description: This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight.
Study NCT00895843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brufen retard
Description: Single dose 2 x 800mg tablets 2 hours prior to surgery
Study NCT00895843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
Study NCT00895843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
Study NCT00895843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
Study NCT01226628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 2476
Study NCT01226628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iTrack Model 275 micro catheter
Description: CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
Study NCT01537627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months.
Study NCT01537627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
Study NCT00264160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107
Study NCT03808350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Families Invited to Be Present at Procedures
Description: Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
Study NCT03808350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Control
Description: Family members will not be invited to remain in the ICU room
Study NCT01633008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Workshop
Description: The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
Study NCT05073029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition program and modification of physical activity
Description: nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
Study NCT05073029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)
Description: one synbiotic sachet (3g), BID, for 3 month traetment
Study NCT05073029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: vitamin D3, oral, 2000IU BID, for 3 month treatment
Study NCT01007136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
Study NCT01007136 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
Study NCT04298450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active SMS Intervention
Description: Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
Study NCT04298450 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham SMS
Description: Single welcome message letting participant know they will be contacted to book an appointment.
Study NCT02870816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Engineered Skin Substitute
Description: Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
Study NCT02870816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.
Study NCT02870816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.
Study NCT02870816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amnionic Membrane Graft
Description: Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
Study NCT00932698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT04080674 — intervention group
Intervention type: OTHER
Intervention: Feed-back controlled deep brain stimulation
Description: Feed-back controlled deep brain stimulation
Study NCT03873415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration
Study NCT01577615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patterned Experience
Description: * The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~* Nonnutritive sucking will be offered to infants.~* Blood work will be collected for inflammatory cytokines.~* Saliva will be collected for genetic analysis~* Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~* All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~* Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~* Follow up visits will occur at 2,6and 24 months corrected age.
Study NCT03573219 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Description: The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
Study NCT05392439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: transcutaneous auricular vagal nerve stimulation
Study NCT05392439 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-taVNS
Description: transcutaneous stimulation at the elbow area
Study NCT03161002 — intervention group
Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study NCT01609309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy.
Study NCT01609309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience.
Study NCT01306045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
Study NCT01306045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-2206
Description: Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
Study NCT01306045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
Study NCT01306045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
Study NCT01306045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
Study NCT01306045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
Study NCT01306045 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
Study NCT04264234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Ultrasonography
Description: Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
Study NCT04264234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
Study NCT01755520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg twice daily dose
Study NCT01755520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg once daily
Study NCT01755520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Ticagrelor
Description: Placebo
Study NCT01755520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Aspirin
Description: Placebo
Study NCT03341650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Pasta
Description: Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
Study NCT03341650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Pasta
Description: Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
Study NCT01722318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide
Study NCT01722318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03826134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PXT012253
Description: Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
Study NCT04517422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
Study NCT04517422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
Study NCT03687450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE yoga-based program
Description: The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga \& Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
Study NCT03016793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puerarin
Description: purabone (puerarin) is a bone graft used for surgical repair of bony defects.
Study NCT03016793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β- tricalcium phosphate
Description: β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
Study NCT03016793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β- tricalcium phosphate alone
Description: β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
Study NCT04410887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC+SOX+OLAPARIB
Description: SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
Study NCT03651232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: once weekly group yoga class for 12 weeks
Study NCT03651232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support group
Description: once weekly group support class for 12 weeks
Study NCT04291105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VV1
Description: VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
Study NCT04291105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
Study NCT03023111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sbv
Description: Standard treatment for CL, parenteral drug used during 20 days.
Study NCT03023111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine plus placebo
Description: Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
Study NCT03023111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine plus GM-CSF
Description: Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
Study NCT04199767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Description: Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
Study NCT04199767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Description: Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
Study NCT04390672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPRAFLEX Cruz
Description: Percutaneous Coronary Intervention for multivessel disease
Study NCT04390672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY
Description: Percutaneous Coronary Intervention for multivessel disease
Study NCT06582407 — intervention group
Intervention type: OTHER
Intervention: Mathematical Prediction of unforseen patient reorientation
Description: The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery
Study NCT02710994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0209
Description: Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
Study NCT02710994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losec
Description: Losec 40 mg
Study NCT00811746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozerem (Ramelteon)
Description: 8 mg taken orally 30 minutes before a split-night PSG
Study NCT00811746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lunesta (Eszopiclone)
Description: 3 mg taken orally 30 minutes before the start of a split-night PSG
Study NCT00811746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Historical Controls
Description: Chart review matched for demographics and comorbidities of the study drug groups.
Study NCT01791634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: proximal chevron osteotomy
Study NCT01791634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal open wedge osteotomy with LPS system
Study NCT01143623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
Study NCT01143623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
Study NCT01143623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01805193 — intervention group
Intervention type: OTHER
Intervention: Computed tomography myocardial perfusion imaging
Study NCT01805193 — intervention group
Intervention type: OTHER
Intervention: Oxygen 15 labelled water positron emission tomography
Study NCT02600182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure
Description: Bilevel positive airway pressure twice per day during the hospital stay.